Results of a phase II trial of combined chemotherapy for patients with diffuse malignant mesothelioma of the pleura.

BACKGROUND: Malignant pleural mesothelioma is associated with a poor mesothelioma prognosis because of its resistance to treatment. The authors conducted a Phase II trial in which two drugs (etoposide and 5-fluorouracil) were added to the Cancer and Leukemia Group B cisplatin-mitomycin regimen in an effort to define a more effective chemotherapy.

METHODS: Forty-five mesothelioma patients with confirmed Stage 2 mesothelioma were prospectively enrolled in the study. Thirty-one patients received cisplatin 60 mg/m2 on Day 1, 5-fluorouracil 600 mg on Days 1-4, folinic acid 100 mg/m2 on Days 1-4, mitomycin C 10 mg/m2 on Day 3, and etoposide 100 mg/m2 i.v. on Days 1-3, with prophylactic hematopoietic growth factors. Fourteen patients received cisplatin, 5-fluorouracil, folinic acid, and mitomycin C with the protocol unchanged, and oral etoposide 50 mg on Days 1-21 without growth factors (1 cycle every 28 days). Histology included epithelial (in 33 cases), sacromatous (in 6), mixed (in 3), and unspecified type (in 3).

RESULTS: Two hundred eleven cycles were administered. Treatment was well tolerated and the major toxicity was hematologic: anemia in 30% of cases, neutropenia in 24%, and 2 probable cases of mitomycin-induced pneumonitis. The objective response rate was 38% (17 of 45 were partial responses), and the median response duration was 12 months. The median survival time was 16 months. There were no differences in response or survival rate between the 31 patients treated with growth factors and the 14 patients treated without them. Survival was slightly better for responders than for nonresponders who had stable malignant mesothelioma or progression (20 vs. 10 months, P<0.05).

CONCLUSIONS: This four-drug combination was effective, with a notably high response rate, acceptable toxicity, and good adherence to protocol doses. The impact on survival was limited.

Source

PMID: 10223568, UI: 99238079
Click here to order or save article

If you have any questions regarding treatment options or your legal rights, please contact us.

Free Mesothelioma Information Packet

Enter your information to receive a comprehensive mesothelioma packet free of charge at your doorstep within 24 hours.

Yes   No

Mesothelioma Mesothelioma Treatment Asbestos Cancer Asbestos Exposure Mesothelioma News Veterans & Mesothelioma Mesothelioma Attorney FREE Case Evaluation Top Mesothelioma Doctors

Robert N. Taub, M.D.
Dr. Robert Taub serves as director of Columbia’s Mesothelioma Center, where he is developing combined chemotherapeutic and surgical techniques that are highly effective in combating mesothelioma.

Randall Trowbridge, M.D.
Dr. Randall Trowbridge is board certified in both internal medicine and medical oncology and specializes in gastrointestinal malignancies with Indiana Oncology Hematology Consultants.

David Rice, M.D.
Dr. David Rice is an Associate Professor and Assistant Surgeon at The University of Texas M.D. Anderson Cancer Center where he serves as the director of the Minimally Invasive Surgery and Mesothelioma programs.

This website is certified by Health On the Net Foundation. Click to verify. We comply with the HONcode standard for trustworthy health information:
verify here.